SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.



Cadila Healthcare gets approval for gLodosyn

This is a small product and not very significant for Cadila Healthcare.

Cadila Healthcare’s subsidiary Zydus Pharmaceuticals USA Inc., has received final approval for Carbidopa 25mg. This is a generic equivalent of Lodosyn 25mg tablets manufactured by Aton Pharma.

Carbidopa 25 mg, including its brand and generics had US sales of ~$32mn and most of which were generated by generics. Lupin also has approval for gLodosyn.

We believe that Cadila will be able to make $1-2mn from this product, and hence, not a significant product for the company.

Nse&Bse tips, Intraday tips is also the part of our advisory recommendations you can also know more if you are interested in Financial Trading to click here subscribe us free >>Bonaz Capital